Navigation Links
Emerging Capital Partners Invests $47.3 Million in North African Personal Care Company
Date:5/21/2008

Societe d'Articles Hygieniques to develop additional production facilities,

increase exports

WASHINGTON, May 21 /PRNewswire/ -- Emerging Capital Partners (ECP), an international private equity firm focused on investing across the African continent, today announced a U.S. $47.3 million investment in Societe d'Articles Hygieniques (SAH), Tunisia's leading personal care company and producer of absorbent hygiene products. The funds will be used to expand operations in SAH's existing North African markets, as well as to enter into new markets.

"ECP believes SAH is poised for continued strong growth thanks to improving standards of living in the North African market and changes in consumer habits that directly benefit hygiene and personal care products," said Tom Gibian, chief executive officer of ECP. "The company already has strong brand recognition, a coherent product line, and competitive production costs. Combined with the region's improving macro fundamentals, SAH is well positioned to expand throughout North Africa."

Over the past five years, SAH's revenue has grown in excess of 30 percent a year, and the company has more than doubled its return on equity. The company - which produces baby care, feminine care, incontinence care, and related paper products under the "Lilas" brand - intends to expand its product range in Tunisia, grow its market share in Algeria and Libya, and accelerate its development in Mauritania and sub-Saharan Africa.

"SAH is an established player in Tunisia and has an excellent track record of expanding into new markets and products," said Vincent Le Guennou, executive vice president of ECP. "The company has formed impressive distribution networks and has adapted its packaging to fit its various markets. This has enabled SAH's export business to grow to more than 40 percent of overall sales, which we view as a positive indicator for future success."

The investment in SAH was
'/>"/>

SOURCE Emerging Capital Partners
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. 2008 American Academy of Pediatric Dentistry Annual Session Highlights Emerging Scientific Advancements
2. Video/Online Games For Health Come Of Age: Four Major Trends Now Emerging
3. Symposium Targets Critical Manufacturing Topics for Emerging Growth Companies
4. Emerging Ultrasound Market to Grow Rapidly Over Next Five Years
5. Normal weight obesity: An emerging risk factor for heart and metabolic problems
6. Perrigo Company to Present at the 12th Annual Sidoti Emerging Growth Institutional Investor Forum
7. Abaxis, Inc. to Present at the Sidoti & Company Twelfth Annual New York Emerging Growth Institutional Investor Forum
8. Scientists say tropics are next emerging disease hotspot
9. inVentiv Clinical Expands Operations to Emerging Latin American Region
10. Current and Emerging Therapies Have No Advantage Over Pfizers Lyrica in Their Effect on Patients Quality of Life in the Treatment of Diabetic Neuropathy
11. Kensey Nash to Participate in the Sidoti Twelfth Annual New York Emerging Growth Institutional Investor Forum Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Mike Lucas of GE Healthcare Recognized as the Lifeline for Minority Businesses; Receives the MMBDC 2009 President's Award 2Health News:The Kenneth Rainin Foundation Awards $457,000 in Grants to Support Dance, Theater, Film and Early Literacy in the San Francisco Bay Area 2Health News:The Kenneth Rainin Foundation Awards $457,000 in Grants to Support Dance, Theater, Film and Early Literacy in the San Francisco Bay Area 3Health News:Webmedx Announces #1 Ranking in KLAS 2009 Transcription Services Report 2Health News:Webmedx Announces #1 Ranking in KLAS 2009 Transcription Services Report 3Health News:Astronaut Balancing Act: Training to Help Explorers Adapt to a Return to Gravity 2Health News:Astronaut Balancing Act: Training to Help Explorers Adapt to a Return to Gravity 3Health News:Astronaut Balancing Act: Training to Help Explorers Adapt to a Return to Gravity 4Health News:Nerve-cell transplants help brain-damaged rats fully recover lost ability to learn 2Health News:Nerve-cell transplants help brain-damaged rats fully recover lost ability to learn 3
Breaking Medicine Technology:TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13Roper Industries Completes the Acquisition of Verathon, Inc. 2Roper Industries Completes the Acquisition of Verathon, Inc. 3delSECUR CORPORATION Announces Agreement to Purchase the Intellectual Property Assets of the Corporation 9666 1delSECUR CORPORATION Announces Agreement to Purchase the Intellectual Property Assets of the Corporation 9666 2Advances in lung cancer research announced at conference 55064 1Advances in lung cancer research announced at conference 55064 2Fecal DNA methylation detects gastric and colorectal cancers 55060 1Fecal DNA methylation detects gastric and colorectal cancers 55060 2
Other Medicine Technology:Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 2Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 4